PD-L1 Antibody (2340D) [Alexa Fluor™ Plus 405]

• Reactivity: Hu
• Clone: 2340D
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Alexa Fluor Plus 405

PD-L1 Antibody (2340D) [Alexa Fluor™ Plus 405] Summary

• Specificity: Detects human PD-L1/B7-H1 in direct ELISAs.
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for PD-L1 Antibody (2340D) [Alexa Fluor™ Plus 405]

• Avelumab
• B7-H
• B7H1
• B7-H1
• B7H1PDCD1L1
• CD274 antigenMGC142294
• CD274 molecule
• CD274
• PDCD1L1
• PDCD1LG1
• PDCD1LG1MGC142296
• PDL1
• PD-L1
• PD-L1B7 homolog 1
• PDL1PDCD1 ligand 1
• programmed cell death 1 ligand 1
• Programmed death ligand 1

Background

B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H1 consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (2). Within the ECD, human B7-H1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (3). B7-H1 is expressed on
inflammatory-activated immune cells including macrophages, T cells, and B cells (4-7), keratinocytes (8, 9), enothelial and intestinal epithelial cells (8, 10), as well as a variety of carcinomas and melanoma (11, 12). B7-H1 binds to T cell B7-1/CD80 and PD-1 (7, 8, 12-15). It suppresses T cell activation and proliferation (5, 8, 14, 16) and induces the apoptosis of activated T cells (11). It plays a role in the development of immune tolerance by promoting T cell anergy (7, 14) and enhancing regulatory T cell development (16). B7-H1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (5, 10) and inhibits the development of Th17 cells (16). In cancer, B7-H1 provides resistance to T cell mediated lysis, enhances EMT, and enhances the tumorigenic function of Th22 cells (6, 9, 12, 15).

1. Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
2. Dong, H. et al. (1999) Nat. Med. 5:1365.
3. Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
4. Tamura, H. et al. (2001) Blood 97:1809.
5. Chen, L. et al. (2007) J. Immunol. 178:6634.
6. Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
7. Tsushima, F. et al. (2007) Blood 110:180.
8. Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
9. Cao, Y. et al. (2010) Cancer Res. 71:1235.
10. Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
11. Dong, H. et al. (2002) Nat. Med. 8:793.
12. Azuma, T. et al. (2008) Blood 111:3635.
13. Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
14. Park, J.-J. et al. (2010) Blood 116:1291.
15. Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
16. Herold, M. et al. (2015) J. Immunol. 195:3584.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.